Iovance Biotherapeutics Inc [NASDAQ: IOVA] closed the trading session at $14.10. The company report on March 22, 2024 at 5:30 PM that Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4).
The awards were granted under Iovance’s 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022 and May 10, 2023, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $15.02, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”), and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stocks have a year to date performance of 73.43 percent and weekly performance of -5.56 percent. The stock has been moved at 217.57 percent over the last six months. The stock has performed -19.29 percent around the most recent 30 days and changed 58.61 percent over the most recent 3-months.
If compared to the average trading volume of 10.44M shares, IOVA reached to a volume of 4104384 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Iovance Biotherapeutics Inc [IOVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $26.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Iovance Biotherapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 20, 2023. While these analysts kept the previous recommendation, Barclays dropped their target price from $40 to $18. The new note on the price target was released on September 18, 2023, representing the official price target for Iovance Biotherapeutics Inc stock. Previously, the target price had yet another raise from $11 to $17, while Wells Fargo kept a Overweight rating on IOVA stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc is set at 1.06, with the Price to Sales ratio for IOVA stock in the period of the last 12 months amounting to 3309.47. The Price to Book ratio for the last quarter was 6.18, with the Price to Cash per share for the same quarter was set at 1.00.
IOVA stock trade performance evaluation
Iovance Biotherapeutics Inc [IOVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.56. With this latest performance, IOVA shares dropped by -19.29% in over the last four-week period, additionally plugging by 217.57% over the last 6 months – not to mention a rise of 129.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 49.72, with the RSI for the last a single of trading hit 43.41, and the three-weeks RSI is set at 53.59 for Iovance Biotherapeutics Inc [IOVA]. The present Moving Average for the last 50 days of trading for this stock 12.15, while it was recorded at 14.61 for the last single week of trading, and 7.74 for the last 200 days.
Iovance Biotherapeutics Inc [IOVA]: An insightful look at the core fundamentals
Iovance Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.79.
Earnings per share (EPS) analysis for Iovance Biotherapeutics Inc [IOVA] stock
With the latest financial reports released by the company, Iovance Biotherapeutics Inc posted -0.5/share EPS, while the average EPS was predicted by analysts to be reported at -0.74/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 32.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IOVA.
Iovance Biotherapeutics Inc [IOVA]: Institutional Ownership
The top three institutional holders of IOVA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in IOVA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in IOVA stock with ownership which is approximately 5.8325%.
